Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest bone metastases Stories

2013-05-15 12:34:17

WAYNE, N.J., May 15, 2013 /PRNewswire/ -- Intended for U.S. Media Only -- Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) approved Xofigo(®) (radium Ra 223 dichloride) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease. Xofigo is the first and only alpha particle-emitting radioactive therapeutic agent approved by the FDA that has demonstrated...

2013-04-18 08:32:50

TIRAT CARMEL, Israel, April 18, 2013 /PRNewswire/ -- InSightec Ltd. announced today that the US Centers for Medicare & Medicaid Services (CMS), a federal agency within the US Department of Health and Human Services (HHS), has created a new billing code for MR guided focused ultrasound treatment of pain palliation of metastatic bone lesions and has established a Medicare payment rate for hospital outpatient departments. InSightec's ExAblate received Food and Drug...

2013-03-19 15:02:19

The initial study results of the Zometa European Study (ZEUS) showed no difference in the incidence of bone metastases between the Zometa group and control arm, said Prof. Manfred Wirth during the closing and fourth plenary session of the 28th Annual EAU Congress which ends today. "There is no difference in the incidence of bone metastases and there is no difference in survival," said Wirth in his brief presentation on whether Zometa can prevent bone metastases in high risk, metastatic...

2013-02-13 00:20:41

WAYNE, N.J., Feb. 13, 2013 /PRNewswire/ -- Bayer HealthCare announced today that the New Drug Application (NDA) for its investigational oncology compound Radium Ra 223 Dichloride (radium-223) has been accepted for filing and granted priority review by the U.S. Food and Drug Administration (FDA). The application is currently under review for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases. "We are pleased the FDA has granted priority review...

2012-12-14 08:24:45

WAYNE, N.J., Dec. 14, 2012 /PRNewswire/ -- Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for radium Ra 223 dichloride (radium-223), an investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases. "If approved, radium-223 has the potential to play a key role in the treatment of men with CRPC that has metastasized to the...

2012-10-22 07:29:06

TIRAT CARMEL, Israel, October 22, 2012 /PRNewswire/ -- InSightec Ltd, the leader in magnetic resonance imaging (MRI)-guided Focused Ultrasound therapy, announced that the U.S. Food and Drug Administration (FDA) has approved ExAblate(R) MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it...

2012-07-18 06:37:41

(Ivanhoe Newswire) — Investigators from the Vanderbilt Center for Bone Biology have discovered that stress can promote the colonization of breast cancer cells in bone. Mice studies revealed that the activation of the sympathetic nervous system (the "fight or flight" response) primes the bone environment for breast cancer cell metastasis. Researchers were able to prevent breast cancer cell lesions in bone using propranolol, a cardiovascular medicine that inhibits sympathetic nervous...

2012-06-22 06:22:47

NEW YORK, June 22, 2012 /PRNewswire/ -- When weighing prostate cancer treatment options, potential side effects such as urinary control and sexual potency are the hot buttons. Seldom discussed, though significantly more damaging, is bone disease. Early diagnosis of prostate cancer, and the right treatment path, can drastically reduce a man's risk of developing prostate cancer-related bone disease. (Photo: http://photos.prnewswire.com/prnh/20120622/NY28935 ) World renowned prostate surgery...

2012-06-19 02:27:07

ALBANY, New York, June 19, 2012 /PRNewswire/ -- New Report Added in ResearchMoz Reports Database Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar...

2012-06-11 21:32:02

Study of a new drug treatment represents a new protocol for those with advanced prostate cancer that has spread to bone Prostate cancer patients with advanced tumors that have spread to bone have a poor chance of surviving. Patients with the disease may now live longer with a new line of radioisotope therapy, say researchers at the Society of Nuclear Medicine's 2012 Annual Meeting. The skeletal systemis the number one metastatic site in patients with prostate cancer. Bone metastases...